Advertisement

La chimiothérapie intrapéritonéale de consolidation

  • C. Tournigand
  • A. Plantade
  • A. de Gramont
Part of the Abord clinique book series (ONCOLPRAT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Weisberger AS, Levine B, Storaasli JP (1955) Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 159(18): 1704–7PubMedGoogle Scholar
  2. 2.
    Bonte FJ, Storaasli JP, Weisberger AS (1956) Comparative evaluation of radioactive colloidal gold and nitrogen mustard in the treatment of serous effusions of neoplastic origin. Radiology 67(1): 63–6PubMedGoogle Scholar
  3. 3.
    Dedrick RL, Myers CE, Bungay PM et al. (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1): 1–11PubMedGoogle Scholar
  4. 4.
    Los G, Mutsaers PH, Lenglet WJM et al. (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25: 389–94CrossRefPubMedGoogle Scholar
  5. 5.
    Menczer J, Ben-Baruch G, Rizel S et al. (1992) Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission. Gynecol Oncol 46: 222–5CrossRefPubMedGoogle Scholar
  6. 6.
    Tarraza HM, Boyce CR, Smith WG et al. (1993) Consolidation intraperitoneal chemotherapy. Gynecol Oncol 50: 287–90CrossRefPubMedGoogle Scholar
  7. 7.
    Dufour P, Bergerat JP, Barats JC et al. (1994) Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer 73: 1865–9PubMedGoogle Scholar
  8. 8.
    Barakat RR, Almadrones L, Venkatraman ES et al. (1998) A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 69(1): 17–22CrossRefPubMedGoogle Scholar
  9. 9.
    Barakat RR, Sabbatini P, Bhaskaran D et al. (2002) Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-Up. J Clin Oncol 20(3): 694–8CrossRefPubMedGoogle Scholar
  10. 10.
    Topuz E, Eralp Y, Saglam S et al. (2004) Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer. Gynecol Oncol 92(1): 147–51CrossRefPubMedGoogle Scholar
  11. 11.
    Tournigand C, Louvet C, Molitor JL et al. (2001) Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma. Gynecol Oncol 83(2): 198–204CrossRefPubMedGoogle Scholar
  12. 12.
    Tournigand C, Louvet C, Molitor JL et al. (2002) Consolidation intraperitoneal chemotherapy in advanced ovarian cancer with pathological complete response or with microscopical residual disease. A GERCOR study. ASCO 883Google Scholar
  13. 13.
    Piccart MJ, Floquet A, Scarfone G et al. (2003) Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 13Suppl 2: 196–203PubMedGoogle Scholar
  14. 14.
    Berek JS, Markman M, Blessing JA et al. (1999) Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Gynecol Oncol 74(1): 48–52CrossRefPubMedGoogle Scholar
  15. 15.
    Berek JS, Markman M, Stonebraker B et al. (1999) Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study. Gynecol Oncol 75(1): 10–4CrossRefPubMedGoogle Scholar
  16. 16.
    Nardi M, Cognetti F, Pollera CF et al. (1990) Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study. J Clin Oncol 8(6): 1036–41PubMedGoogle Scholar
  17. 17.
    Willemse PH, de Vries EG, Mulder NH et al. (1990) Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. Eur J Cancer 26(3): 353–8PubMedGoogle Scholar
  18. 18.
    Pujade-Lauraine E, Guastalla JP, Colombo N et al. (1996) Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J. Clin Oncol 14(20: 343–50PubMedGoogle Scholar
  19. 19.
    Bruzzone M, Rubagotti A, Gadducci A et al. (1997) Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. Gynecol Oncol 65(3): 499–505CrossRefPubMedGoogle Scholar
  20. 20.
    Stewart JA, Belinson JL, Moore AL et al. (1990) Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 50(19): 6302–10PubMedGoogle Scholar
  21. 21.
    Steis RG, Urba WJ, VanderMolen LA et al. (1990) Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 8(10): 1618–29PubMedGoogle Scholar
  22. 22.
    Freedman RS, Edwards CL, Kavanagh JJ et al. (1994) Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol 16(3): 198–210PubMedGoogle Scholar
  23. 23.
    de Gramont A, Gangji D, Louvet C et al. (2002) Adoptive immunotherapy of ovarian carcinoma. Gynecol Oncol 86(1): 102–3PubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • C. Tournigand
  • A. Plantade
  • A. de Gramont

There are no affiliations available

Personalised recommendations